Oncolytics Biotech Inc T.ONC

Pfizer's Trillium & GBT M&A deals not the last

[Noteable]

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development should help replace future declining vaccine sales and lost revenue from patent expirations.

 

[fox7mf]

Hopefully this news applies directly to Onc, and PFE finally absorbs this biotech. I'm sure they're feeling the pressure from Roche to do so.GL.

[Noteable]

Pfizer acquired preclinical Trillium Therapeutics in August 2021 for US$2.3 Billion, then Biohaven Pharmaceuticals in May 2022 for US$11.6 Billion and Global Blood Therapeutics in October 2022 for US$5.4 Billion (both of these last 2 deals being completed in October 2022) .... and now in Pfizer's Q3 earning report provided in November 2022 the company stated that the M&A activity recently

[Noteable]

Interestingly, Pfizer didn’t proactively seek a Global Blood Therapeutics (GBT) acquisition in the first place given the significant risk associated with the development of a sickle cell drug. The first contact with GBT was made by another company, which on May 26 asked to buy out the sickle cell disease (SCD) specialist for $55 per share, the securities filing show. In the months that 

[Noteable]

Consequently, over the past two years, Pfizer has significantly ramped up its deal-making in an effort to add $25 billion of risk-adjusted revenue by 2030. And as already outline, here are Pfizer's most significant deals over this period: COMPANY NAME PRICE TAG KEY ASSETS Arena Pharmaceuticals $6.7 billion

[Noteable]

Reposted from November: Pfizer acquired preclinical Trillium Therapeutics in August 2021 for US$2.3 Billion, then Biohaven Pharmaceuticals in May 2022 for US$11.6 Billion and Global Blood Therapeutics in October 2022 for US$5.4 Billion (both of these last 2 deals being completed in October 2022) .... and now in Pfizer's Q3 earning report provided in November 2022 the company stated that the M